Quantum-Si Inc. 10-Q Summary: Quarter Ended September 30, 2025
Business Context and Reporting Period
Quantum-Si Inc. (QSI) is a life sciences company focused on proteomics research, developing a proprietary single-molecule detection platform for Next-Gen Protein Sequencing (NGPS). The company operates as a single reportable segment. This summary covers the quarterly period ended September 30, 2025, and the nine-month period ended on the same date. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $552 | $787 | $1,985 | $1,866 |
| Gross Profit | $194 | $367 | $1,031 | $990 |
| Gross Margin | 35.1% | 46.6% | 51.9% | 53.1% |
| Net Loss | $(35,703) | $(25,313) | $(83,728) | $(67,886) |
| Diluted EPS | $(0.17) | $(0.18) | $(0.44) | $(0.48) |
| Cash & Marketable Securities | $230.5 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $680.4 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline in Q3: Total revenue decreased 29.9% year-over-year in Q3 2025, driven by longer capital sales cycles and budget constraints at customers, particularly those funded by the National Institute of Health (NIH). Conversely, nine-month revenue increased 6.4% due to strong Q1 performance.
- Significant One-Time Expenses: Operating expenses surged due to two major non-recurring items in Q3 2025:
- Lease Termination Expense: $13.6 million recorded to settle a lease dispute and terminate a facility in New Haven, Connecticut.
- Legal Settlements: $1.8 million recorded for settlements related to Delaware stockholder litigation and a contract manufacturer dispute.
- Operating Loss Expansion: Loss from operations increased 41.6% in Q3 and 22.0% for the nine months ended September 30, 2025, primarily attributable to the aforementioned one-time expenses.
- Warrant Liability Gain: The company recognized a $1.5 million gain in Q3 2025 (vs. $0.1 million in Q3 2024) due to a decrease in the fair value of warrant liabilities, driven by changes in the underlying stock price.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash, cash equivalents, and marketable securities ($230.5 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue generating negative operating cash flows until commercial scale is achieved.
- Capital Raising: The company completed two registered direct offerings in 2025 (January and July), raising approximately $93.5 million in net proceeds. A new "at-the-market" (ATM) offering program with Leerink Partners was established in September 2025 with up to $100 million capacity, though no shares were sold under this agreement during the quarter.
- Product Roadmap: The company launched the Platinum Pro benchtop sequencer in January 2025 with first shipments in March. Development continues on the next-generation "Proteus" platform, estimated to launch in the second half of 2026.
- Risks: Key risks include the need for additional financing, potential inability to achieve profitability, reliance on NIH funding for customers, and ongoing legal contingencies. The company also highlighted risks associated with the evolving regulatory landscape for Artificial Intelligence (AI).
Investor Verification Checklist
- One-Time Expense Impact: Verify the sustainability of operating margins by excluding the $13.6 million lease termination and $1.8 million legal settlement expenses from Q3 results.
- Revenue Trajectory: Monitor Q4 revenue to determine if the Q3 decline was a temporary anomaly due to NIH budget cycles or a structural shift in demand.
- Cash Burn Rate: Assess the runway provided by the $230.5 million cash position against the current burn rate, noting the significant cash outflows for settlements and lease termination.
- Legal Contingencies: Confirm the finalization of the Delaware stockholder litigation settlement and the status of the contract manufacturer dispute to ensure no further liabilities arise.
- Equity Dilution: Track the utilization of the new $100 million ATM facility and the remaining capacity on the 2023 shelf registration ($13.8 million) for potential future dilution.